RxDoctor Payments Data

John Crawford, MD

Family Medicine · Germantown, TNNPI 1568406551

Payments from drug & device makers

$15,851in general payments, 2019–2025

Across 556 payments — averaging $28.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Abbott$886
  • GSK$721
  • plus $7K from 34 others

What the payments were for

  • Food & beverage$15,63799%
  • Education$2151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,851 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$246,634
Medicare patients
644
Services billed
5,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide262$295,530
GlyxambiEmpagliflozin/Linagliptin228$227,582
JardianceEmpagliflozin190$207,250
EliquisApixaban155$144,958
FarxigaDapagliflozin Propanediol104$104,160
OzempicSemaglutide106$96,059
Tresiba Flextouch U-200Insulin Degludec106$81,855
JanuviaSitagliptin Phosphate71$79,319
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$54,557
XareltoRivaroxaban47$48,618
LinzessLinaclotide42$41,907
GemtesaVibegron58$37,613
RybelsusSemaglutide20$33,007
TradjentaLinagliptin30$30,274
Breo ElliptaFluticasone/Vilanterol42$28,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance, Tradjenta, Spiriva Respimat$655$471,716461 claims
Lilly USA, LLCMounjaro, Trulicity$1,230$305,386274 claims
PfizerEliquis$463$144,958155 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,121$132,256156 claims
Novo NordiskOzempic, Rybelsus$1,428$129,065126 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$721$106,083159 claims
MerckJanuvia$620$79,31971 claims
AbbVieLinzess, Vraylar, Synthroid$591$62,649116 claims
Johnson & JohnsonXarelto$644$48,61847 claims
Astellas Pharma US IncMyrbetriq$215$14,45226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →